I-Mab shifts focus to givastomig, a bispecific antibody for CLDN18.2-positive tumors, following positive early data and ...

As part of the reshuffle, I-Mab will prioritise the advancement of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, ...

ROCKVILLE, MD, USA I January 6, 2025 I I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision ...

The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

I-Mab, a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment ...

Domvanalimab is under clinical development by Arcus Biosciences and currently in Phase I for Glioblastoma Multiforme (GBM).